A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects.

Trial Profile

A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Preliminary results of pooled minimal residual disease molecular analysis (n=105,RV-MM-EMN441 and RV-MM-COOP0556), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 May 2016 Planned End Date changed from 1 Aug 2013 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top